{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:43:55Z","timestamp":1786196635170,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001249","name":"University of Tasmania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001249","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral anticoagulants (OACs), particularly direct oral anticoagulants (DOACs), may lower dementia risk, but existing studies are constrained by incomplete dementia ascertainment, short follow-up, and lack of evaluation of individual agents or baseline lifestyle-related risk profiles. We examined the association of OAC use and incident dementia in atrial fibrillation (AF) and its variation by LIfestyle for BRAin Health (LIBRA) score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this population-based cohort using linked 45 and Up Study data, participants with a first AF diagnosis between 1 January 2010 and 30 June 2022 were included, excluding those with prior AF or dementia (screened 2004\u20132009). OAC exposure was ascertained from pharmaceutical benefits scheme dispensing records and classified as warfarin or DOACs (dabigatran, rivaroxaban, and apixaban). A six-month landmark period following AF diagnosis was used to define exposure: participants initiating any OAC during this period were classified as OAC users, whereas those without OAC dispensing were classified as non-users. Participants were followed from AF diagnosis until dementia diagnosis, death, or 30 June 2023. Propensity score (PS) based inverse probability of treatment weighting and matching were applied to balance baseline characteristics. Cox proportional hazards models estimated adjusted hazard ratios (HRs) for incident dementia and dementia-related mortality, accounting for demographic, clinical, and lifestyle-related risk factors. Competing-risk analyses were performed to account for mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 21,671 AF patients (mean age 74.2\u00a0years, 45.9% women) with a mean follow-up of 6.0 (3.3) years, OAC use was associated with a lower risk of incident dementia compared with non-use (HR, 0.77; 95% CI, 0.70\u20130.85). DOAC use was associated with lower dementia risk (HR, 0.63; 95% CI, 0.56\u20130.70), whereas warfarin use was associated with higher dementia risk (HR, 1.31; 95% CI, 1.16\u20131.49). Individual DOAC agents were each associated with reduced dementia risk compared with non-use. In head-to-head comparisons, apixaban was associated with a lower dementia risk than dabigatran (HR, 0.79; 95% CI, 0.64\u20130.96). Findings were consistent across PS-matched, competing-risk, and high-adherence sensitivity analyses. Associations were similar in women and men (P for interaction\u2009=\u20090.528) and were stronger among participants aged\u2009\u2265\u200975\u00a0years (HR, 0.66; 95% CI, 0.60\u20130.74; P for interaction\u2009&lt;\u20090.001). However, there was no statistically significant evidence that the association differed across LIBRA strata (P for interaction\u2009=\u20090.699) or ORBIT bleeding risk categories (P for interaction\u2009=\u20090.069), suggesting no clear effect modification by either score. Use of DOACs was also associated with lower dementia-related mortality (HR, 0.53; 95% CI, 0.44\u20130.63).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In people with AF, use of DOACs was associated with a reduced risk of incident dementia and dementia-related mortality, independent of baseline LIBRA score. These findings suggest potential cognitive benefits of DOAC therapy across diverse baseline dementia risk profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11357-026-02468-5","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:28:14Z","timestamp":1786195694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral anticoagulant use and incident dementia in atrial fibrillation by baseline LIBRA score: a population-based cohort study using the 45 and up study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-4327","authenticated-orcid":false,"given":"Eyayaw Ashete","family":"Belachew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Salahudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woldesellassie M.","family":"Bezabhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"2","key":"2468_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2019","unstructured":"Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2019;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"issue":"2","key":"2468_CR2","doi-asserted-by":"publisher","first-page":"38857","DOI":"10.31083\/AP38857","volume":"26","author":"J Wang","year":"2025","unstructured":"Wang J, Zeng HY, Gao JX, Zhong BL. Enhancing dementia awareness and screening, and reducing stigmatizing attitudes towards dementia in urban China: the role of opinion leader intervention in community-dwelling older adults. Alpha Psychiatry. 2025;26(2):38857.","journal-title":"Alpha Psychiatry"},{"issue":"11","key":"2468_CR3","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaneurol.2015.2161","volume":"72","author":"RF de Bruijn","year":"2015","unstructured":"de Bruijn RF, Heeringa J, Wolters FJ, Franco OH, Stricker BH, Hofman A, et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 2015;72(11):1288\u201394.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2468_CR4","doi-asserted-by":"publisher","first-page":"e023098","DOI":"10.1161\/JAHA.121.023098","volume":"11","author":"WM Bezabhe","year":"2022","unstructured":"Bezabhe WM, Bereznicki LR, Radford J, Wimmer BC, Salahudeen MS, Garrahy E, et al. Oral anticoagulant treatment and the risk of dementia in patients with atrial fibrillation: a population\u2010based cohort study. J Am Heart Assoc. 2022;11(7):e023098.","journal-title":"J Am Heart Assoc"},{"key":"2468_CR5","first-page":"69","volume":"7","author":"CY Santos","year":"2017","unstructured":"Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement Diagn Assess Dis Monit. 2017;7:69\u201387.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2468_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2017.09.176","volume":"250","author":"G Tse","year":"2018","unstructured":"Tse G, Wong CW, Gong M, Wong WT, Bazoukis G, Wong SH, et al. Predictive value of inter-atrial block for new onset or recurrent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2018;250:152\u20136.","journal-title":"Int J Cardiol"},{"issue":"19","key":"2468_CR7","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1001\/jama.2015.4369","volume":"313","author":"GY Lip","year":"2015","unstructured":"Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313(19):1950\u201362.","journal-title":"JAMA"},{"issue":"5","key":"2468_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacasi.2023.07.012","volume":"3","author":"KY Fong","year":"2023","unstructured":"Fong KY, Chan YH, Wang Y, Yeo C, Rosario BH, Lip GYH, et al. Dementia risk of direct oral anticoagulants versus warfarin for atrial fibrillation: Systematic review and meta-analysis. JACC Asia. 2023;3(5):776\u201386.","journal-title":"JACC Asia"},{"key":"2468_CR9","first-page":"200282","volume":"21","author":"F Latif","year":"2024","unstructured":"Latif F, Nasir MM, Meer KK, Farhan SH, Cheema HA, Khan AB, et al. The effect of oral anticoagulants on the incidence of dementia in patients with atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol Cardiovasc Risk Prev. 2024;21:200282.","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"11","key":"2468_CR10","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1161\/STROKEAHA.120.033338","volume":"52","author":"S-R Lee","year":"2021","unstructured":"Lee S-R, Choi E-K, Park S-H, Jung J-H, Han K-D, Oh S, et al. Comparing warfarin and 4 direct oral anticoagulants for the risk of dementia in patients with atrial fibrillation. Stroke. 2021;52(11):3459\u201368.","journal-title":"Stroke"},{"issue":"10452","key":"2468_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selb\u00e6k G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572\u2013628.","journal-title":"Lancet"},{"issue":"1","key":"2468_CR12","doi-asserted-by":"publisher","first-page":"38762","DOI":"10.31083\/AP38762","volume":"26","author":"Y Zeng","year":"2025","unstructured":"Zeng Y, Zhang G. Optimizing cognitive health: the promise and challenges of physical-cognitive interventions for dementia and mild cognitive impairment. Alpha Psychiatry. 2025;26(1):38762.","journal-title":"Alpha Psychiatry"},{"issue":"3","key":"2468_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/gps.4245","volume":"30","author":"K Deckers","year":"2015","unstructured":"Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Mu\u00f1oz S\u00e1nchez JL, Anstey KJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30(3):234\u201346.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"2468_CR14","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1002\/alz.13801","volume":"20","author":"J Neuffer","year":"2024","unstructured":"Neuffer J, Wagner M, Moreno E, Le Grand Q, Mishra A, Tr\u00e9gou\u00ebt DA, et al. Association of LIfestyle for BRAin health risk score (LIBRA) and genetic susceptibility with incident dementia and cognitive decline. Alzheimers Dement. 2024;20(6):4250\u20139.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2468_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/gps.4700","volume":"33","author":"OJG Schiepers","year":"2018","unstructured":"Schiepers OJG, K\u00f6hler S, Deckers K, Irving K, O\u2019Donnell CA, van den Akker M, et al. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. Int J Geriatr Psychiatry. 2018;33(1):167\u201375.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2468_CR16","doi-asserted-by":"publisher","first-page":"1527802","DOI":"10.3389\/fcvm.2025.1527802","volume":"12","author":"LJ Huang","year":"2025","unstructured":"Huang LJ, Chen JS, Song YZ, Chang P. Atrial fibrillation and cognitive impairment: mechanisms, influencing factors, and prospects. Front Cardiovasc Med. 2025;12:1527802.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"2468_CR17","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/alz.13577","volume":"20","author":"C Rosenau","year":"2024","unstructured":"Rosenau C, K\u00f6hler S, Soons LM, Anstey KJ, Brayne C, Brodaty H, et al. Umbrella review and Delphi study on modifiable factors for dementia risk reduction. Alzheimers Dement. 2024;20(3):2223\u201339.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2468_CR18","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1093\/ije\/dyac104","volume":"52","author":"K Bleicher","year":"2023","unstructured":"Bleicher K, Summerhayes R, Baynes S, Swarbrick M, Navin Cristina T, Luc H, et al. Cohort profile update: the 45 and Up Study. Int J Epidemiol. 2023;52(1):e92\u2013101.","journal-title":"Int J Epidemiol"},{"key":"2468_CR19","unstructured":"Sax Institute . The Chronic Conditions Umbrella Program Linkage (CUPL) Factsheet. Sydney: Sax Institute; 2023. Available from: https:\/\/www.saxinstitute.org.au\/solutions\/45-and-up-study\/use-the-45-and-up-study\/cupl\/."},{"key":"2468_CR20","unstructured":"NSW Admitted Patient Data Collection held by the NSW Ministry of Health System Information and Analytics Branch."},{"key":"2468_CR21","unstructured":"NSW Emergency Department Data Collection held by the NSW Ministry of Health System Information and Analytics Branch."},{"key":"2468_CR22","unstructured":"NSW Mental Health Ambulatory Data Collection held by the NSW Ministry of Health System Information and Analytics Branch."},{"issue":"3","key":"2468_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/archneurol.2011.31","volume":"68","author":"RS Wilson","year":"2011","unstructured":"Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol. 2011;68(3):351\u20136.","journal-title":"Arch Neurol"},{"key":"2468_CR24","volume-title":"Australian medicines handbook 2024","author":"Australian Medicines Handbook","year":"2024","unstructured":"Australian Medicines Handbook. Australian medicines handbook 2024. Adelaide: Australian Medicines Handbook Pty Ltd; 2024."},{"issue":"7-8","key":"2468_CR25","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1345\/aph.1H018","volume":"40","author":"LM Hess","year":"2006","unstructured":"Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7\u20138):1280\u20138.","journal-title":"Ann Pharmacother"},{"key":"2468_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-025-02056-z","author":"KR Sewell","year":"2026","unstructured":"Sewell KR, Doecke JD, Gardener SL, Stephan B, Erickson KI, Brown BM. Lifestyle for brain health (LIBRA) score, cognition, brain volume, and dementia risk in the UK Biobank. Geroscience. 2026. https:\/\/doi.org\/10.1007\/s11357-025-02056-z.","journal-title":"Geroscience"},{"issue":"7018","key":"2468_CR27","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/bmj.311.7018.1457","volume":"311","author":"A Trichopoulou","year":"1995","unstructured":"Trichopoulou A, Kouris-Blazos A, Wahlqvist ML, Gnardellis C, Lagiou P, Polychronopoulos E, et al. Diet and overall survival in elderly people. BMJ. 1995;311(7018):1457\u201360.","journal-title":"BMJ"},{"key":"2468_CR28","doi-asserted-by":"crossref","unstructured":"Bezabhe WM, Bereznicki LR, Radford J, Wimmer BC, Curtain C, Salahudeen MS, et al. Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation. Frontiers in Pharmacology. 2021;Volume 12 - 2021.","DOI":"10.3389\/fphar.2021.586370"},{"key":"2468_CR29","unstructured":"Sax Institute. 45 and Up Study: Data and technical information [Internet]. Sydney: Sax Institute; [cited 2025 Oct 7]. Available from: https:\/\/www.saxinstitute.org.au\/solutions\/45-and-up-study\/use-the-45-and-up-study\/data-and-technical-information\/."},{"issue":"10","key":"2468_CR30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.hlc.2018.06.1043","volume":"27","author":"D Brieger","year":"2018","unstructured":"Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, et al. National heart foundation of Australia and the cardiac society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ. 2018;27(10):1209\u201366.","journal-title":"Heart Lung Circ"},{"issue":"46","key":"2468_CR31","first-page":"3258","volume":"36","author":"EC O'Brien","year":"2015","unstructured":"O\u2019Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258\u201364.","journal-title":"Eur Heart J"},{"issue":"1","key":"2468_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14\u201320.","journal-title":"Clin Kidney J"},{"issue":"12","key":"2468_CR33","doi-asserted-by":"publisher","first-page":"e1309","DOI":"10.1212\/WNL.0000000000206748","volume":"100","author":"AA Rahman","year":"2023","unstructured":"Rahman AA, Michaud J, Dell\u2019Aniello S, Moodie EEM, Brophy JM, Durand M, et al. Oral anticoagulants and the risk of dementia in patients with nonvalvular atrial fibrillation: A population-based cohort study. Neurology. 2023;100(12):e1309\u201320.","journal-title":"Neurology"},{"issue":"25","key":"2468_CR34","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"key":"2468_CR35","unstructured":"Irwig L, Irwig J, Trevena L, et al. Smart Health Choices: Making Sense of Health Advice. London: Hammersmith Press; 2008. Chapter 18, Relative risk, relative and absolute risk reduction, number needed to treat and confidence intervals. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK63647\/."},{"issue":"1","key":"2468_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239\u201341.","journal-title":"Biometrika"},{"issue":"446","key":"2468_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2468_CR38","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","volume":"368","author":"RD Riley","year":"2020","unstructured":"Riley RD, Ensor J, Snell KIE, Harrell FE Jr., Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441.","journal-title":"BMJ"},{"issue":"12","key":"2468_CR39","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.amjmed.2018.06.035","volume":"131","author":"R Chopard","year":"2018","unstructured":"Chopard R, Piazza G, Gale SA, Campia U, Albertsen IE, Kim J, et al. Dementia and atrial fibrillation: pathophysiological mechanisms and therapeutic implications. Am J Med. 2018;131(12):1408\u201317.","journal-title":"Am J Med"},{"issue":"12","key":"2468_CR40","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.hrthm.2014.08.013","volume":"11","author":"V Jacobs","year":"2014","unstructured":"Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm. 2014;11(12):2206\u201313.","journal-title":"Heart Rhythm"},{"key":"2468_CR41","doi-asserted-by":"publisher","first-page":"7692182","DOI":"10.1155\/2018\/7692182","volume":"2018","author":"E Shavit Stein","year":"2018","unstructured":"Shavit Stein E, Ben Shimon M, Artan Furman A, Golderman V, Chapman J, Maggio N. Thrombin inhibition reduces the expression of brain inflammation markers upon systemic LPS treatment. Neural Plast. 2018;2018:7692182.","journal-title":"Neural Plast"},{"issue":"1","key":"2468_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12877-022-03106-3","volume":"22","author":"DGJ McKechnie","year":"2022","unstructured":"McKechnie DGJ, Patel M, Papacosta AO, Lennon LT, Ellins EA, Halcox JPJ, et al. Associations between inflammation, coagulation, cardiac strain and injury, and subclinical vascular disease with frailty in older men: a cross-sectional study. BMC Geriatr. 2022;22(1):405.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2468_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12877-025-06888-4","volume":"26","author":"HO Abu","year":"2025","unstructured":"Abu HO, Del Castillo FF, Wang W, Saczynski JS, Mehawej J, Tenes P, et al. The prevalence and burden of chronic kidney disease, patterns of anticoagulation prescribing, and major bleeding risk in older adults with atrial fibrillation. BMC Geriatr. 2025;26(1):138.","journal-title":"BMC Geriatr"},{"issue":"9","key":"2468_CR44","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.7326\/M20-7141","volume":"174","author":"DH Kim","year":"2021","unstructured":"Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation\u202f: A cohort study. Ann Intern Med. 2021;174(9):1214\u201323.","journal-title":"Ann Intern Med"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02468-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:28:16Z","timestamp":1786195696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-026-02468-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":44,"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1007\/s11357-026-02468-5","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The conduct of the 45 and Up Study was approved by the University of NSW Human Research Ethics Committee. Ethical approval for this study was granted by the NSW Population & Health Services Research Ethics Committee (Reference Number: 2021\/ETH12383) following review and approval by the Sax Institute Scientific Review Panel. Project access was authorised by the Sax Institute, with data availability commencing in March 2025. Researchers accessed the data securely through the Sax Institute\u2019s Secure Unified Research Environment (SURE). All datasets were de-identified before analysis, with participant-level linkage across databases enabled using unique Sax Institute Project Person Numbers (PPN). All participants provided consent for ongoing follow-up and linkage to routinely collected health data using participant PPN.","order":1,"name":"Ethics","label":"Ethics and consent to participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}